Open an account

Sana Biotechnology

SANA · NASDAQ

$2.36+$0.06 (+2.61%)TodayMarket closed ·
Prev close $2.30

About SANA

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Employees
142
Headquarters
Seattle, Washington
Listed
Feb 4, 2021
Sector
Health Care
Industry
Biotechnology
Website
sana.com

SANA key statistics

Market cap
706.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.64M
Volume
3.53M
Open price
$2.27
High today
$2.42
Low today
$2.25
52 Week high
$5.90
52 Week low
$2.22

Sana Biotechnology (SANA) at a glance

Sana Biotechnology (SANA) last traded at $2.36, with a market cap of 706.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.25 and $2.42. The current price is 4.9% above the day's low and 2.5% below its high.

Volume so far is 3.53M shares, in line with the average of 3.64M shares a day.

Over the past year Sana Biotechnology has ranged from $2.22 to $5.90, and now sits 4% of the way up that range.

Sana Biotechnology met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.1487.

The average analyst price target is $8.60, 264.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $8.60
Low
$6.06
Now
$2.36
High
$12.60

SANA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 6.0% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2547
  2. Q4 FY24: reported -$0.21 per share against an estimate of -$0.2309
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.2342
  4. Q2 FY25: reported -$0.21 per share against an estimate of -$0.211
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.1835
  6. Q4 FY25: reported -$0.21 per share against an estimate of -$0.1355
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.173
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.1487

SANA news

  • Press releaseGlobe Newswire

    Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

  • Press releasePRNewswire

    Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

  • Press releasePRNewswire

    Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

  • Vandana Singh

    Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

Similar companies

Companies in the same industry as Sana Biotechnology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.